Financials
Financial year 2025
CellCarta from Antwerpen, company number BE0474654355, closed financial year 2025 with a result of € 7.7 million after tax. For that financial year CellCarta recorded revenue of € 79.9 million and equity of € 25.9 million. Compared with financial year 2024, the result moved from € 8.8 million to € 7.7 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.
€ 25.9 million
▲ 42% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7.7 million
▼ 12% vs 2024
Profit after tax over the fiscal year.
€ 7.3 million
▼ 52% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 24.8 million.
People and assets in 2025
242.7
▲ 6.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 23.1 million
▲ 14% vs 2024
€ 95,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2.3 million
▲ 85% vs 2024
Of which on lease € 1.4 million.
Debts at end 2025
€ 3.4 million
▲ € 2.8 million vs 2024
€ 346,097 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 10.9 million
▼ 40% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 78 days on average.
€ 6.4 million
▲ 15% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 53,081,660 | € 58,617,714 | € 74,025,203 | € 79,878,333 | ▲ 8% |
| Profit after taxes | € -7,599,892 | € 860,125 | € 8,793,487 | € 7,698,401 | ▼ 12% |
| Equity | € 8,513,394 | € 9,373,519 | € 18,167,006 | € 25,865,408 | ▲ 42% |
| Total debts | € 35,806,712 | € 40,600,995 | € 39,719,857 | € 34,605,296 | ▼ 13% |
| Cash | € 5,123,560 | € 9,040,172 | € 15,188,452 | € 7,290,194 | ▼ 52% |
| Land & buildings | € 1,197,916 | € 1,143,136 | € 1,114,267 | € 1,319,587 | ▲ 18% |
| Retained profit | € 7,451,394 | € 8,311,519 | € 17,105,006 | € 24,803,408 | ▲ 45% |
| Bank debt | € 1,289,292 | € 1,022,759 | € 591,640 | € 3,437,867 | ▲ € 2.8 million |
| Balance sheet total | € 44,320,106 | € 49,974,514 | € 57,886,863 | € 60,470,703 | ▲ 4% |
| Employees (FTE) | 206.5 | 225 | 236.4 | 242.7 | ▲ 6.3 |
Key figures of CellCarta, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CellCarta?
What happened at CellCarta in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Elliot Miller stepped down as director. NBB
- Hendriks Consulting Company BV stepped down as director. NBB
- Joshua Schultz stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 7.7 million (▼ 12% vs 2024). Source: NBB ↗
- Maurice Tenney III stepped down as director. NBB
- Kockx - Consulting BV stepped down as director. NBB
- New establishment in Antwerpen. KBO
- Kockx - Consulting BV became a director. NBB
In short
From € 7.6 million loss in 2022 to € 7.7 million profit in 2025.
Paid € 6.8 million in corporate taxes since 2022.
Best year ever: 2024, with € 8.8 million profit.
Pays suppliers within 78 days on average.
A new publication or filing at CellCarta? We notify you, reason included.
Follow CellCartaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Histogenex Holding NV (83.3%) and Cellcarta NV (16.7%). It owns 100% of CellCarta China Ltd and 18.5% of PATHOMATION itself.
Directors
According to the 2025 annual accounts
since 2023 · until 2026
since 2025 · until 2031
since 2019 · until 2025
Managing director · represented by Mark Kockx
Also active at: BATYO, PATHOMATION, HistoGeneX Holding, Arsenal IO Belgium
since 2025 · until 2026
since 2022 · until 2025
since 2025 · until 2030
Hendriks Consulting Company BV
Managing director · represented by Dirk Hendriks
Also active at: HistoGeneX Holding, Arsenal IO Belgium
since 2025 · until 2031
Shareholders
83.3%
16.7%
Participations
CellCarta China Ltd
100%
18.5%
Establishments
Establishment units
Physical locations of this company
Sint-Bavostraat 78
2610 Antwerpen
Sneeuwbeslaan 20
2610 Antwerpen
Active since 1 December 2025
Neerlandweg 11
2610 Antwerpen
Active since 1 January 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0474.654.355
- VAT number
- BE 0474.654.355
- Registered office
- Sint-Bavostraat 78, 2610 Antwerpen
- Names & denominations
- CellCarta
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 April 2001
- Peppol
- Active · Active since 14 Oct 2025
- Contact
- [email protected] +32 3 502 05 00
- Activities · NACE
Activiteiten van medische beeldvorming en medische laboratoria
Medische laboratoria
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied